Catalent and S.Biomedics join forces to advance groundbreaking Parkinson’s therapy
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
